Tehran University of Medical Sciences Journal of Pharmaceutical Care 2322-4630 7 3 2019 12 28 72 79 Ștefana Stăcescu University of Medicine, Pharmacy, Science and Technology of Tîrgu Mureș, Faculty of Pharmacy, Department of Pharmaceutical Chemistry Gabriel Hancu University of Medicine, Pharmacy, Science and Technology of Tîrgu Mureș, Faculty of Pharmacy, Department of Pharmaceutical Chemistry Denisa Podar University of Medicine, Pharmacy, Science and Technology of Tîrgu Mureș, Faculty of Pharmacy, Department of Pharmaceutical Chemistry Ștefania Todea Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy from Tîrgu Mureș, Tîrgu Mureș, Romania Amelia Tero-Vescan University of Medicine, Pharmacy, Science and Technology of Tîrgu Mureș, Faculty of Pharmacy, Department of Biochemistry 2019 06 28 2019 08 11 Relatively few medications are available for the management of obesity and all are indicated as adjuncts to increased physical activity, caloric restriction and lifestyle modification. Among different weight-loss drugs, the most intriguing and controversial class is the one of anorexic amphetamines, due to their high efficiency but also relevant side-effects. Several previously approved anorexic amphetamines like fenfluramine, phenylpropanolamine, phenmetrazine and sibutramine have been withdrawn from the market due to unanticipated adverse effects. Nowadays only four amphetamine derivatives are approved for short-term treatment of obesity: amfepramone, benzphetamine, phendimetrazine and phentermine. The article provides an overview of both the history, and the current status, of the use of amphetamine derivatives in the obesity pharmacotherapy. https://jpc.tums.ac.ir/index.php/jpc/article/view/274